AlphAIAlphAI — Financial news for AI agents
BenzingaJUN 102 min read$ATNM

Life Sciences Investor Forum Agenda Announced for June 11th-12th - Adia Nutrition (OTC:ADIA), Actinium Pharma (AMEX:ATNM)

NEW YORK, June 10, 2025 ( GLOBE NEWSWIRE ) -- Virtual Investor Conferences, the leading proprietary investor conference series announced the agenda for the Life Sciences Investor Forum June 11th & 12th. This event is co-hosted by Zacks Small Cap Research.

Original reporting
Benzinga · Globe Newswire
Published Jun 10, 2025, 6:38 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 10, 2025, 7:30 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefFinancial news
Primary signal
$ATNM
Neutral
medium confidence
Mentioned
$ATNM
Relevance
6/10
AlphAI data visualization · based on Benzinga
Decision brief

The 30-second read

$ATNMNeutralMed
01

Why it matters

Such events can influence stock prices based on disclosures and investor sentiment.

02

Market read

Event relevance is moderate; potential for short-term stock movements in participating companies.

03

What to watch

Market-wide uncertainties or macroeconomic factors could overshadow sector-specific events.

Relevance 6/10Timing: short-term (within 1-2 weeks)

Background

The Life Sciences Investor Forum is a key event where biotech and life sciences companies present updates to investors.

Company-level read

Ticker impact

$ATNMNeutralMedium confidence
Context

Biopharmaceutical sector, focus on oncology and rare diseases.

Expected impact

Potential slight increase (+3%) with positive disclosures; otherwise, negligible impact.

Evidence & confidence

Event relevance is industry-specific; actual impact depends on company disclosures during the event.

Market effects

Sector

Potential uplift in biotech and life sciences sectors.

Regional

Limited regional impact, primarily US-based companies.

Global

Moderate, depending on international investor participation.

Counterpoint

What could challenge this read

The event may not lead to significant stock movements if no material news is announced.

Key entities

  • Research Firm
    Zacks Small Cap Research

    Co-host of the event, providing analysis and insights.

Read at source← All news

Related articles

OCT 15
$ATNMMedAI 8/10

Actinium Pharmaceuticals Announces Oral Presentation at EANM 2026 Highlighting First-in-Human Phase 1 Study of ATNM-400, a Non-PSMA Targeting Radiotherapy, in Prostate Cancer

Actinium Pharmaceuticals (ATNM) announced early Phase 1 trial results for ATNM-400, a non-PSMA targeted radiotherapy for metastatic castration-resistant prostate cancer (mCRPC), to be presented at EANM 2026. The study assesses safety, biodistribution, and dosimetry of Zirconium-89-labeled ATNM-400, aiming to inform therapeutic dosing with Actinium-225-labeled ATNM-400.

prnewswire.com2 min
OCT 15
$ATNMMedAI 8/10

Some prostate cancers progress after targeted therapy. Actinium is testing radiation aimed at a different target.

Actinium Pharmaceuticals presented early Phase 1 trial data for ATNM-400, a non-PSMA targeted radiotherapy for metastatic castration-resistant prostate cancer (mCRPC). The study aims to assess safety, biodistribution, and dosimetry of Zirconium-89-labeled ATNM-400, with plans to advance to Actinium-225-labeled therapy. According to the company, ATNM-400 targets a novel antigen and could benefit a broad mCRPC patient population, including those resistant to PSMA-directed therapies.

stocktitan.net2 min
AUG 14
$ATNMMed

Actinium Pharmaceuticals Announces Actimab-A Intellectual Property and Manufacturing Advances and Provides NYSE American Listing Update

Actinium Pharmaceuticals (NYSE American: ATNM) said it expanded Actimab-A intellectual property with multiple newly issued US patents and additional pre-grant/allowed applications, covering uses in AML, MDS, and solid tumors, including combinations with venetoclax and CLAG-M. The company also amended its IND to add a manufacturing source and reported NYSE American listing compliance plan acceptance through Nov. 27, 2027.

prnewswire.com4 min
MAY 29
$ATNMLow

Actinium Pharmaceuticals Receives Two Patent Allowances Spanning Its Actimab-A and Iomab-ACT Programs

Actinium Pharmaceuticals said the Canadian Intellectual Property Office issued Notices of Allowance for two patent applications covering its Actimab-A and Iomab-ACT programs. The Actimab-A/CLAG-M AML combination allowance is expected to issue with a term into Jan. 2039; the CD45 conditioning for gene-edited cell therapies is expected to issue with a term into Oct. 2038. Actinium said this adds to a global portfolio of about 250 issued and pending patents.

prnewswire.com3 min
MAY 29
$ATNMMedAI 9/10

Actinium Pharmaceuticals to Present ATNM-400 Program Update at SNMMI 2026 Conference on May 31-June 2 and Provides NYSE American Listing Standards Notice

Actinium Pharmaceuticals (NYSE American: ATNM) said it will present new ATNM-400 (Actinium-225 antibody radioconjugate) data at SNMMI 2026 in Los Angeles May 30–June 2, with three posters on prostate cancer, NSCLC, and radioconjugate optimization. Separately, NYSE American notified the company it is not in compliance with $4.0m stockholders’ equity requirements; Actinium must submit a compliance plan by June 26, 2026.

prnewswire.com4 min
OCT 15
$NFLXMed

Bela Bajaria Is Out at Netflix, Peter Rice Is In

Netflix announced Bela Bajaria is stepping down as Chief Content Officer, replaced by Peter Rice. Ted Sarandos praised her decade of service. This follows Netflix's recent layoffs of 1,000 employees. Bajaria led content expansion, including unscripted programming and live events.

vulture.com2 min